FDA data Registry peer set 1 peer

Alternatives to dalbavancin

1 same-class SPL records vs dalbavancin - uses, FAERS reaction fields, and OTC/Rx flags from public FDA sources.

Brand: Dalvance

Lipoglycopeptide Antibiotic Prescription 1 alternative found

About dalbavancin

Dalbavancin is an antibiotic medicine. It fights bacterial infections of the skin and tissues under the skin.

Used for: Dalbavancin treats acute bacterial skin and skin structure infections (ABSSSI). These infections are caused by certain types of bacteria. It can treat infections caused by Staphylococcus aureus, Streptococcus pyogenes, and other bacteria.

1 Lipoglycopeptide Antibiotic peers (wide set)

Compare dalbavancin vs oritavancin side-by-side →

dalbavancin vs oritavancin · FAERS reaction fields

FAERS top-reaction field "Pruritus" shows the widest count spread between dalbavancin and oritavancin in this extract (107-report gap on that field). Counts are exposure-weighted submissions, not prevalence rates.

Side Effect dalbavancin oritavancin
Rash 93 84
Back Pain 55 81
Pruritus 55 162
Dyspnoea 53 74
Nausea 49 67
Hypersensitivity 45 33
Erythema 42 58
Vomiting 42 41

"-" means no reports for that reaction. Report counts reflect total FAERS submissions, not prevalence rates.

dalbavancin peer mix vs class inventory

Peer mix

0 OTC and 1 Rx SPL records in this peer set (1 total). Class inventory for Lipoglycopeptide Antibiotic: 2 drugs.

Frequently Asked Questions

What same-class SPL records sit beside dalbavancin?
This registry lists 1 Lipoglycopeptide Antibiotic medication records beside dalbavancin, including oritavancin. Grouping is therapeutic-class indexing from openFDA/SPL, not a product recommendation.

Reading a wide Lipoglycopeptide Antibiotic peer set (1 records)

dalbavancin (Dalvance) sits in a wide Lipoglycopeptide Antibiotic peer set (1 of 1 class peers shown). Labeled indication field for dalbavancin: Dalbavancin treats acute bacterial skin and skin structure infections (ABSSSI).

Top FAERS reaction fields for dalbavancin total 499 reports across 10 reactions, set beside oritavancin. Counts are exposure-weighted submissions, not per-patient risk.

Registry note: Therapeutic-class peer lists are registry indexes, not prescribing advice. This information is for educational purposes only and is not a substitute for professional medical advice. Do not stop or change your medication without talking to your doctor or pharmacist.

Full dalbavancin profile →

Field note for dalbavancin: see also the generic vs brand label guide when reading Dalvance SPL strings.